Compare AFLAC Incorporated (AFL) vs Revvity Inc (RVTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs Revvity Inc — how do they compare? AFLAC Incorporated trades at $121.29 (market cap $61.84B), while Revvity Inc trades at $108.81 (market cap $12.50B). The key difference: AFLAC Incorporated is far larger — about 4.9× Revvity Inc's market cap, and AFLAC Incorporated pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AFL | RVTY | |
|---|---|---|
Market Cap | $61.84B | $12.50B |
Sector | Financials | Technology |
52-Week High | $121.49 | $117.75 |
52-Week Low | $98.09 | $82.26 |
Enterprise Value | $70.50B | $14.99B |
Dividend Yield | 2.01% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
Revvity (RVTY) trades at $112.95, down 0.71% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent AI integration announcements with Anthropic's Claude platform highlight ongoing innovation in scientific R&D workflows.
The stock presents a mixed outlook with strong earnings performance and AI-driven growth initiatives offset by elevated valuation multiples. Key risks include margin pressure and competitive threats in the life sciences sector. Analyst consensus leans bullish with a $109.38 price target, though current price exceeds this level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
